Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vonoprazan

vonoprazan

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vonoprazan

23 trials tracked of vonoprazan: 9 in phase 3 or 4 and 7 with published results. The most-cited published study has 294 citations.

23Trials tracked
9Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 2 Phase 3 7 Phase 2 2 Phase 1 7 Other / NA 5
  1. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection Completed · 294 cited
  2. Phase 3 Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Completed · 151 cited
  3. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Completed · 146 cited
  4. Phase 4 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Completed · 43 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) Completed · 30 cited
  6. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis Completed · 13 cited
Show 17 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection Completed · 5 cited
  2. Phase 4 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed
  3. Phase 3 Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) Completed
  4. Phase 2 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI) Completed
  5. Phase 2 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Completed
  6. Phase 1 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease Completed
  7. Phase 1 A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants Completed
  8. Phase 1 A Study of Vonoprazan in Adults With Helicobacter Pylori Completed
  9. Phase 1 A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily Completed
  10. Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants Completed
  11. Phase 1 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease Completed
  12. Phase 1 Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants Completed
  13. N/A Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use" Completed
  14. N/A Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis" Completed
  15. N/A Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication" Completed
  16. N/A Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use" Completed
  17. N/A Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use" Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance
Gastroenterology Sys. Review
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance H. pylori treatments failing as resistance grows, review finds
This narrative review synthesizes current H. pylori eradication strategies, noting that clarithromycin resistance exceeds 15%-20% in most re…
Clarithromycin resistance now tops 15-20% in most regions, but bismuth quadruple and other combos still clear the bug over 85% of the time.
Frontiers Jul 29, 2026
Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori
Infectious Disease RCT
Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori New vonoprazan treatments show promise for clearing H. pylori infection
This multicenter randomized controlled trial of 579 H. pylori-positive patients found that vonoprazan-amoxicillin (VA) dual therapy demonstr…
Two new simplified drug combinations could offer a simpler way to clear H. pylori infections, especially for patients with certain allergies…
Frontiers Jul 5, 2026
WeChat-based patient-doctor interaction improves patient experience in H. pylori infection treatment
Oncology RCT
WeChat-based patient-doctor interaction improves patient experience in H. pylori infection treatment A WeChat chat group did not improve stomach bug cure rates compared to standard care
This randomized controlled trial evaluated a WeChat-based patient-doctor interaction system versus routine patient education in treatment-na…
A chat group with doctors did not cure more stomach bugs than standard education, though patients felt better using the app.
Frontiers May 30, 2026
Narrative review of vonoprazan for pediatric H. pylori infection
Infectious Disease Sys. Review
Narrative review of vonoprazan for pediatric H. pylori infection New drug class could simplify hard-to-treat stomach infections in kids
This narrative review synthesizes evidence on vonoprazan-based regimens for Helicobacter pylori infection in pediatric populations. The auth…
A new stomach acid blocker might help clear infections in kids, but doctors need more proof before using it widely.
Frontiers May 13, 2026
Meta-analysis finds vonoprazan-based therapies achieve 94% H. pylori eradication in Asian populations
Infectious Disease Meta-analysis
Meta-analysis finds vonoprazan-based therapies achieve 94% H. pylori eradication in Asian populations The Two-Drug Combo Clearing Stomach Bacteria Where Others Are Failing
A systematic review and meta-analysis of 7,498 Asian patients with Helicobacter pylori infection compared vonoprazan-amoxicillin regimens to…
A new two-drug combo clears stomach bacteria in 94% of Asian patients, outperforming standard treatments where others are failing.
Apr 14, 2026
Vonoprazan-based regimens show higher H. pylori eradication rates than rabeprazole dual therapy in Chinese cohort
Anesthesiology & Pain Medicine Cohort
Vonoprazan-based regimens show higher H. pylori eradication rates than rabeprazole dual therapy in Chinese cohort A New Stomach Infection Treatment Works Where Old Ones Often Fail
A retrospective cohort study of 598 H. pylori-positive outpatients in Guizhou, China, found vonoprazan-based regimens achieved eradication r…
For millions struggling with a common and stubborn stomach bug, a new treatment approach just proved it can succeed where standard care freq…
Frontiers Apr 11, 2026